Abigail Batchelder, M.P.H., Ph.D., clinical psychologist and associate professor at Boston University, explains the effect that shame can have on the healthcare outcomes of HIV patients and why “explicit compassion” is a step in the right direction when treating these individuals.
Romidepsin is approved to treat adults with cutaneous T-cell lymphoma. Ameal’s generic has received designation for 180 days of exclusivity.
Blood-based tests are less sensitive but might increase adherence.
A newly developed prognostic model may help clinicians better estimate survival in patients with non-small cell lung cancer and brain metastases treated with immune checkpoint inhibitors.
By partnering with pastors to navigate religious taboos and collaborating with public health agencies, researchers Jannette Berkley-Patton, Ph.D., and Kathryn Derose, Ph.D., demonstrated that African American churches — long-standing pillars of their communities — can serve as trusted, effective sites for HIV testing that reach not only congregants but also the broader community, helping to address the disproportionate impact of HIV on African Americans.
Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.
Hospital pharmacy leaders cite a potential rebate model transition for the 340B program as one of their biggest worries amid rising manufacturer restrictions and evolving federal compliance requirements.
The workforce challenge in healthcare is not going away. Health systems and health plans can cope with it by rethinking how work can be divided between humans and artificial intelligence.
The FDA has approved Epiduo for over-the-counter use, a combination acne gel previously available only by prescription, a decision experts say could expand access to effective treatment for the millions of Americans who face cost and logistical barriers to dermatological care.
Real-world data presented at ASCO also show that at 12 month and 24 months, patients treated with Brukinsa had a higher probability of survival than those treated with other BTK inhibitors.
Peterson Philanthropies announced a commitment of $50 million to set up the public benefit company that will provide employers with healthcare pricing and quality data.
C. Brooke Adams, Pharm.D., BCOP, of Orlando Health discusses bispecific antibody therapies for multiple myeloma.
Mike Badome is chief actuary of Arcadia, an outcomes company that helps healthcare organizations improve cost, quality and operational performance.
Bahar Davidoff, Pharm.D., MBA, is founder and principal of Davidoff Strategy and Consulting, a healthcare advisory firm focused on healthcare operations, pharmacy strategy and artificial intelligence (AI) integration.
Sham Firdausi, M.P.H., M.Sc., MBA, is deputy chief financial officer of the Santa Clara Valley Healthcare, one of the largest public health systems in the country and California’s second-largest county-owned health and hospital system.
Zach Jones, Pharm.D., is senior director of clinical formulary strategy, Prime Therapeutics, a Minnesota-based pharmacy benefit manager.
How Banjo Health uses generative AI to speed prior authorizations, cut paperwork, and scale fair, transparent utilization management across plans.
HaVy Ngo-Hamilton, Pharm.D., senior pharmacy director, Buzz Health, a healthcare technology company offering prescription savings solutions that integrate with health systems to promote price transparency and cost-effectiveness.
Brianna Oddi, Pharm.D. Brianna Oddi, Pharm.D., is senior clinical account manager of PANTHERx Rare Pharmacy
Carly Rodriguez, Pharm.D., is vice president and chief pharmacy officer, Moda Health and immediate past president of the Academy of Managed Care Pharmacy
Alyana Samai, M.P.H., is corporate vice president, neuroscience and musculoskeletal services, at LCMC Health, an eight-hospital, New Orleans-based nonprofit health system.
Lorece Shaw, Pharm.D., is director of clinical account consulting at Capital Rx, a pharmacy benefit and management company.
The second-line drug for metastatic pancreatic cancer is pan-RAS inhibitor that recruits cyclophilin A to stick to RAS proteins, explains Subham Pant, M.D., M.B.B.S., of The University of Texas MD Anderson Cancer Center.
Javier Cortes, M.D., Ph.D., discusses KEYNOTE-522 findings showing pembrolizumab plus chemotherapy delivers durable survival gains in high-risk early-stage TNBC after nearly 8 years of follow-up.
Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, was awarded for his work in cancer immunoprevention and his efforts to develop a cancer vaccine for those who are carriers of Lynch mutations.
Treatment after treatment for second-line treatment for pancreatic cancer has failed in clinical trials. Daraxonrasib seems to have broken the losing streak, says MD Anderson's Shubman Pant, M.D., M.B.B.S.
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody that achieved 28-month median survival in advanced squamous non-small cell lung cancer.
A phase 3 clinical trial presented at ASCO 2026 found that combining talazoparib with enzalutamide reduced the risk of cancer progression by 52% compared with enzalutamide alone in prostate cancer patients with specific DNA repair gene mutations, with even greater benefit seen in those carrying BRCA mutations.
Lead ARACOG trial investigator Alicia Morgans, M.D., discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.
A new investigational combination therapy for advanced KRAS G12C-mutant non-small cell lung cancer showed "highly promising" results with “manageable” side effects, according to the study’s lead author.
